FORMYCON AG news, videos and press releases - Page 4
For more news please use our advanced search feature.
FORMYCON AG - More news...
FORMYCON AG - More news...
- DGAP-Adhoc: FYB201, Formycon's biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA
- DGAP-News: Formycon Reports First Quarter 2022 Financial Results and Announces Development Start of two New Biosimilar Candidates FYB208 and FYB209
- DGAP-News: Formycon publishes Update on Development Projects
- DGAP-News: Formycon appoints Dr. Stefan Glombitza as CEO and sets the course for the future by appointing the two experienced pharmaceutical managers Nicola Mikulcik and Dr. Andreas Seidl to the Executive Board
- DGAP-Adhoc: Formycon announces changes to its Executive Board
- DGAP-News: Formycon Publishes Annual Financial Statements for the 2021 Financial Year
- DGAP-News: United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) grants Marketing Authorization for FYB201, Formycon's Biosimilar for Lucentis®1 to be Commercialized by Teva as ONGAVIA®
- DGAP-Adhoc: FYB201, Formycon's Biosimilar for Lucentis®1 achieves Marketing Authorization in United Kingdom
- DGAP-News: Formycon AG and ATHOS KG announce closing of transaction to acquire biosimilar assets FYB201 and FYB202 as well as Bioeq GmbH
- DGAP-News: Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG
- DGAP-Adhoc: Formycon and ATHOS KG merge development activities through the acquisition of biosimilar assets in a long-term strategic partnership
- DGAP-News: MS Pharma becomes Partner for the Commercialization of FYB201, Formycon's Biosimilar Candidate to Lucentis(R)1 (ranibizumab), in the MENA Region
- DGAP-News: Formycon and Scientists from TUM publish new Data on broadly effective SARS-CoV-2 antiviral Drug FYB207
- DGAP-News: Formycon Reports its Nine-Month Figures for 2021
- DGAP-News: Formycon and SCG Cell Therapy Announce Collaboration and License Agreement for Formycon's COVID-19 Drug FYB207
- DGAP-Adhoc: Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region
- DGAP-Adhoc: Formycon and Bioeq announce File Acceptance for FYB201, a biosimilar candidate to Lucentis(R) (ranibizumab) by the U.S. Food and Drug Administration (FDA)
- DGAP-News: Formycon Reports on Virtual Annual General Meeting 2021
- DGAP-News: Formycon Publishes Half-Year Results for 2021
- DGAP-News: Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021
- DGAP-News: Formycon reports on the status of FYB207 development
- DGAP-Adhoc: Formycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA)
- DGAP-Adhoc: Formycon receives Euro 12.7 million grant for further development of COVID-19 drug FYB207 as part of the Bavarian Therapy Strategy to combat the COVID-19 pandemic
- DGAP-Adhoc: Formycon and Bioeq announce submission of the marketing authorization application for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the European Medicines Agency (EMA)
- DGAP-News: Teva Pharmaceutical Industries Ltd. becomes strategic partner for the commercialization of FYB201, Formycon's biosimilar candidate to Lucentis(R)1 (ranibizumab) in Europe, Canada, Israel and New Zealand
- DGAP-Adhoc: Formycon announces conclusion of exclusive commercialization agreement between Bioeq AG and Teva Pharmaceutical Industries Ltd. for FYB201 in Europe, Canada, Israel and New Zealand
- DGAP-News: Formycon Publishes Annual Financial Statements for the 2020 Financial Year
- DGAP-News: Formycon receives approval for early action for COVID-19 drug FYB207 as part of a grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (StMWi)
- DGAP-News: Formycon's COVID-19 Drug FYB207 even more efficient against SARS-CoV-2 Mutant B.1.1.7
- DGAP-News: Formycon and Leukocare cooperate in the development of high-quality biopharmaceuticals
